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Abstract  
The management of intracranial germ cell tumours (ICGCT) is complex. It was agreed at the 
2013 Third International ICGCT Symposium (Cambridge, UK) to undertake a multi-
disciplinary Delphi process to identify consensus in their management. Seventy-seven 
delegates from the Symposium were selected as suitable experts and were invited to 
participate in the Delphi survey; 64 (83%) responded. Those invited represented multiple 
disciplines from the Far East, Australasia, Europe and America. Thirty-eight consensus 
statements, encompassing aspects of work-up, staging, treatment and follow-up, were 
prepared. To achieve consensus, statements required ≥70% agreement from ≥60% of 
respondents. Overall, 34/38 statements (89%) met consensus criteria. This international 
Delphi approach has defined key areas of consensus which will guide and streamline future 
management of ICGCT. In addition, it has identified areas of different understanding and 
practice internationally which should be the focus of future collaborative studies. Such efforts 
will likely translate into improved patient outcomes. 
 
Keywords: consensus; Delphi; GCT; germ cell tumour; germinoma; intracranial; ICGCT; 
non-germinomatous germ cell tumour (NGGCT) 
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Background  
Intracranial germ cell tumours (ICGCTs) represent a rare and histologically heterogeneous 
group of predominantly midline neoplasms. Incidence varies markedly across continents, 
with North American (SEER-CBTRUS) and international (IARC) data
1
 showing overall 
incidence rates of 0.6/million in the United States (US), 1/million in Europe, to 2.7/million in 
Japan
2
. The classification systems and terminology used to describe ICGCTs is controversial. 
Histologically, these tumours are often segregated into three groups, namely pure germinoma, 
teratoma and ‘non-germinomatous’ germ cell tumours (the latter will subsequently be 
referred to as NGGCT throughout). NGGCT are often mixed tumours, and include those with 
yolk sac tumour (YST), embryonal carcinoma (EC) and/or choriocarcinoma (CHC) 
components
2
. Confusingly, NGGCT may also contain germinoma and/or teratoma which 
challenge some classification systems. 
Diagnostic methods also vary, with some countries relying on surgical (histological) 
verification for diagnosis upfront, often with a gross total resection rather than biopsy
2
. 
Others diagnose GCTs without primary surgery based on tumour marker elevation in the 
presence of consistent radiological appearances. The tumour markers utilised for this purpose 
are alpha-fetoprotein (AFP; typically raised in the presence of YST) and human chorionic 
gonadotrophin (HCG; typically raised in the presence of CHC). Elevation of AFP or HCG 
above a defined threshold in either the serum or cerebrospinal fluid (CSF) is taken to indicate 
the presence of these specific malignant components and confirms the diagnosis of a 
‘secreting’ NGGCT. It should be noted, however, that marker thresholds vary across 
continents, based on historical experience. Surgical biopsy is reserved for ‘marker-negative’ 
patients, where neither AFP nor HCG is raised beyond the threshold
2
. 
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Classification systems for ICGCTs reflect the excellent overall survival (OS) for patients with 
germinoma and the inferior survival for those with NGGCTs. Three risk groups are identified 
in Japanese treatment stratifications, namely pure germinoma, intermediate-prognosis 
ICGCTs and poor-prognosis tumours, the latter two groups comprising mixed malignant 
NGGCTs
3
. Historically, in Europe and America, two risk groups were identified (germinoma 
and NGGCT). More recently, patients with diagnostic serum or CSF AFP level more than 
1000 IU/L have been identified in Europe as a high-risk NGGCT group
4
, for which the 
benefit of treatment intensification is currently being tested. Final results of the Children’s 
Oncology Group NGGCT trial (ACNS 0122) including children from North America and 
Australia are due to be reported shortly
5
. 
Not surprisingly, given these differing diagnostic and classification approaches, the evolution 
of treatment by neurosurgeons, radiation oncologists, and medical or pediatric oncologists 
has resulted in diverse treatment strategies
2
. Principles of treatment include the necessity to 
deliver radiotherapy (RT) in all cases of germinoma and NGGCT in order to achieve good 
cure rates, except in infants and very young children where a chemotherapy only approach is 
often attempted in order to avoid the devastating long-term sequelae of RT. Given inferior 
survival in NGGCT, higher RT doses have been employed with less scope for the dose 
reductions that have been possible for pure germinoma
2
. Chemotherapy has been used for 
both germinoma and NGGCT; this has facilitated reductions in RT fields and/or doses in 
germinoma by some groups, with the aim of reducing or sparing late-effects of treatment
2
. 
Generally, the mainstay of treatment for teratoma without malignant transformation is 
surgery which is curative for the majority of patients if a gross total resection can be 
achieved
2
. 
As a consequence of these complexities, which include relative difficulty of surgical access, 
the lack of diagnostic markers for some cases, response to both chemotherapy and RT, and 
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the frequent presence of endocrine complications, optimal management of patients with 
ICGCTs necessitates the input of multiple disciplines and a collaborative approach to care
2
. 
In addition, the paucity of ICGCT specimens available for molecular analysis has hampered 
our understanding of the pathogenesis of ICGCTs. Recently, this has been addressed by the 
formation of consortia facilitating the publication of key biological findings
6,7
. In the future, 
the aim will be to incorporate molecular markers into clinical trials of this rare disease, in 
order to assist diagnosis and inform prognostic and treatment strategies
2
. 
As a result of these challenges, there have now been three international symposia focussing 
specifically on ICGCT management, with a fourth taking place in Tokyo in 2015. The First 
Symposium was held in Kyoto, Japan, in 2003, followed by the Second in Los Angeles, US 
in 2005
2
. A number of the key controversies in the management of ICGCTs were highlighted 
during these meetings. Outputs from these early symposia, for example, included the 
reporting of surgical management guidelines
8
. The aims of the Third Symposium, held in 
Cambridge in 2013, were to further increase our clinical and biological understanding of 
ICGCTs, to overcome differences where necessary and to reach consensus where possible
2
. 
In total, 117 delegates attended from 25 countries across five continents, representing the 
multidisciplinary specialities involved in the management of ICGCTs. From these initial 
discussions, a committee was formed (MJM, UB, RN, JF, MM, JCN) which developed 
Delphi consensus statements
9,10
, covering wide-ranging aspects of ICGCT management. 
These were subsequently subjected to online voting by representative selected experts who 
attended the Third Symposium. The results of this multi-disciplinary Delphi method, and the 
challenges that remain, are described below. 
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Methods: Consensus process  
There was a preliminary discussion of possible areas for international consensus at the Third 
International ICGCT Symposium held on the 17
th 
- 20
th
 of April 2013, in Cambridge, UK. In 
attendance were 117 delegates from five continents, including invited recognised experts in 
the field and those who had submitted abstracts. At the symposium, it was agreed that Delphi 
consensus statements
10
 would subsequently be drafted. A representative committee of six 
individuals representing Asia, America and Europe was responsible for this process [MJM 
(UK), UB (Canada), RN (Japan), JF (US), MM (Japan), and JCN (UK)]. 
Figure 1 provides details of the consensus process. Of the 117 symposium delegates, 77 
recognised experts in their respective national/international groups were invited to participate 
in the Delphi process. Thirty-one were from Europe (40%), 26 from Asia (34%) and 20 from 
America (26%). Sixty-four (83%) experts responded [25 Europe (39%); 23 Asia (36%); 16 
America (25%)]; this figure was set as the initial denominator for subsequent Delphi voting. 
Thirty-eight consensus statements, encompassing various aspects of work-up, staging, 
treatment and follow-up, were prepared by the Delphi committee between December 2013 
and June 2014, using Delphi consensus methodology
10
. Voting and responses were collated 
using a web-based survey tool (SurveyMonkey; www.surveymonkey.com). The statements 
were distributed for a first round of voting between October 2014 and November 2014. 
Participants were asked to rate each statement with four possible responses, as follows: ‘I 
support the statement’, ‘I would support the statement with modification’, ‘I do not support 
the statement’, as described11 or, additionally, ‘I do not have the experience in this area to be 
able to comment’. If respondents selected this last response, their vote did not count towards 
the denominator (i.e. the total number of responses recorded for that statement). In addition, a 
free text comments section was included below each statement to allow for suggested 
modifications. If a participant did not agree with the statement completely, they were strongly 
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encouraged to make comments to explain their rationale. If ≥70% of votes were in support of 
a statement from ≥60% of participants in each round of voting, it was accepted, as 
described
11. Where <70% consensus occurred, statements were revised based on respondents’ 
comments and re-distributed in a second and final round of voting between November 2014 
and December 2014. Accepted statements are described below in the Results and Discussion 
sections. The themes and comments behind the rejection of unsuccessful statements are also 
summarised in the Discussion; these statements reflecting the current lack of consensus will 
help to focus future discussions and research. 
 
Methods: Search Strategy and Selection Criteria 
References for this article were identified through searches of PubMed relevant to the Delphi 
statements, particularly where areas of non-consensus were highlighted. Articles were also 
identified through searches of the authors’ own files. In particular, where published full 
manuscripts were lacking in a certain area, published abstracts were considered. Only 
manuscripts and abstracts published in English were reviewed. The final reference list was 
generated on the basis of originality and relevance to the scope of the Delphi consensus 
process. 
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Results: Consensus statements 
Fifty-seven participants (89%) voted in the first round and 29/38 statements (76%) met 
consensus criteria. Nine statements were revised based on participants’ comments and re-
distributed for voting. This included one statement that was initially accepted, but which was 
rewritten for greater clarity (Statement 15) and two others that were revised into a single 
statement (Statement 30). Forty-nine participants (77%) voted in the second round, and six of 
the revised statements were passed. In all, 34 statements met consensus criteria from the 
original 38 statements (89%) and are listed below. 
 Description of intracranial germ cell tumours (ICGCTs) 
Statement 1. A new name(s) to describe 'non-germinomatous' ICGCTs is required.  
 Overall therapeutic purpose 
Statement 2. The current overall aim of management in intracranial germinoma is to 
maintain excellent OS whilst attempting to minimise the late-effects of treatment.  
Statement 3. The current overall aim of management in intracranial GCT (ICGCT) with non-
germinomatous malignant components [yolk sac tumour (YST), embryonal carcinoma (EC), 
and choriocarcinoma (CHC)] is to improve OS.  
Statement 4. All patients with ICGCT should be treated in a center with experience of 
managing these rare and complex tumours. 
Statement 5. Multi-disciplinary team discussion involving core members (including 
neuroradiologists, neuropathologists, neurosurgeons, oncologists and radiation oncologists) 
should be the basis for all diagnostic and management decisions for patients with ICGCT.  
 Radiological staging work-up 
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Statement 6. Where MRI is available, patients with suspected ICGCT should have MRI head 
with at least pre- and post-contrast enhanced T1 weighted images, and sagittal MRI spine 
post-contrast, at the time of diagnostic work-up and subsequently during treatment and 
follow-up.  
 Cytological staging work-up 
Statement 7. Where treatment protocol decisions are based on the result of CSF cytology, 
then CSF cytology examination at ICGCT diagnosis, once acute hydrocephalus is under 
control, and before treatment commences, is essential.  
Statement 8: In ICGCT patients where CSF cytology is performed, lumbar CSF is preferred 
to ventricular CSF.  
 Biochemical work-up 
Statement 9. All patients with possible ICGCT (based on imaging and presentation) should 
have serum AFP and HCG markers measured at diagnosis.  
Statement 10: All patients with possible ICGCT (based on imaging and presentation) should 
have CSF AFP and HCG markers measured at diagnosis, unless medically contra-indicated.  
Statement 11. CSF AFP and HCG markers should preferably be measured at the same time 
as serum markers in patients with suspected ICGCT.  
Statement 12. The site from which the CSF sample was obtained for markers and cytology 
(lumbar/ventricular) should be clearly documented in patients with suspected ICGCT.  
 Management of symptomatic obstructive hydrocephalus  
Statement 13. The initial surgical management of obstructive hydrocephalus in patients with 
presumed ICGCT is CSF diversion, regardless of the provisional tumour type or markers.  
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Statement 14. If CSF diversion is necessary in ICGCT patients, CSF should be taken for 
tumour markers (AFP, HCG) first.  
Statement 15: For patients with ICGCTs, an endoscopic third ventriculostomy (ETV), where 
feasible, is the favoured surgical intervention for obstructive hydrocephalus.  
Statement 16: For patients with ICGCTs, if ETV is not possible, then placement of an 
external ventricular drain (EVD), where feasible, is favoured over a permanent ventricular 
shunt.  
 Diagnosis - the role of surgery  
Statement 17. Patients with AFP and/or HCG levels (serum and/or CSF) below national 
protocol thresholds require surgical biopsy for ICGCT diagnosis, regardless of imaging 
findings.  
Statement 18. Patients with consistent radiological imaging and AFP and/or HCG elevation 
(serum and/or CSF) above nationally defined protocol thresholds do not require surgical 
biopsy for ICGCT diagnosis, but instead treatment may be initiated, based on the diagnosis 
suggested by the markers.  
 Diagnosis - the role of histopathology  
Statement 19. The World Health Organization (WHO) classification of tumours of the 
Central Nervous System should be used as the current international standard for pathological 
classification of ICGCTs.  
Statement 20. The minimum immunohistochemical panel for ICGCT diagnostic work-up 
should include all of the following: i) CD117/KIT (for germinoma) ii) POU5F1 (OCT3/4) 
(germinoma), iii) PLAP (germinoma), iv) AFP (yolk sac tumour), v) CD30 (embryonal 
carcinoma) and vi) HCG (CHC or syncytiotrophoblast within germinoma).  
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  Treatment for teratoma  
Statement 21. Complete surgical resection, where feasible, is the treatment of choice for 
intracranial mature and immature teratomas without malignant transformation.  
 Treatment for pure germinoma  
Statement 22. Based on current knowledge, patients with intracranial germinoma should 
receive RT to maximise their chance of cure.  
Statement 23. For localised germinoma, focal RT fields alone are insufficient, and therefore, 
RT should also include at least the ventricles (i.e. at least whole ventricular RT).  
Statement 24. Chemotherapy is an effective strategy to reduce the dose of RT for localised 
germinoma.  
 Treatment for malignant ICGCTs with non-germinomatous components 
Statement 25. All patients with ICGCTs containing malignant non-germinomatous 
components (i.e. NGGCTs) should receive a combination of chemotherapy and RT, to 
maximise their chance of cure.  
Statement 26. For patients with metastatic ICGCTs containing malignant non-
germinomatous components (i.e. NGGCTs), craniospinal RT should be included in the 
treatment plan.  
Statement 27. For patients with ICGCTs containing malignant non-germinomatous 
components, residual disease should be surgically resected, if feasible, prior to completion of 
therapy.  
 Follow-up  
Statement 28. Serum tumour markers should be monitored during treatment and follow-up 
for ICGCTs, even if initially negative.  
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 Management of relapsed ICGCTs following optimal first line treatment  
Statement 29. All patients with symptomatic, radiological or marker detected ICGCT relapse 
should be fully re-staged and assessed, prior to considering management options.  
Statement 30. Relapsed germinoma patients are salvageable with variable, but not yet 
standardised, treatment regimens.  
Statement 31. For patients with relapsed ICGCTs containing malignant non-germinomatous 
components (i.e. NGGCTs), who are to be treated with curative intent, high-dose 
chemotherapy with haematopoietic stem cell rescue should be employed, with surgery and 
additional RT where feasible.  
 Banking of tissue/material for biological research  
Statement 32. Where national provision for tumour banking is available, and after 
appropriate ethical consents, the banking and storage of ICGCT tissue, where available 
(ideally fresh frozen but formalin fixed paraffin embedded if not), serum, CSF and 
constitutional DNA should be undertaken.  
 Late-effects and Quality of Life (QoL) studies  
Statement 33. QoL questionnaires should be mandated in future ICGCT clinical trials.  
Statement 34. Assessments for late-effects related to the tumour itself, associated 
hydrocephalus, surgery, chemotherapy and RT are essential components of long-term follow-
up for patients with ICGCT.  
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Discussion  
Overview. There are no previously published reports of consensus in the field of intracranial 
germ cell tumours (ICGCTs), a rare and heterogeneous cancer type. International discussions 
and collaboration, facilitated through three international ICGCT symposia, have allowed the 
initiation of the described consensus process using Delphi methodology
2
. The 77 delegates 
from the Third Symposium who were invited to take part (and the 64 who responded) were 
recognised experts in the field, from multiple disciplines and many different countries and 
continents. This ensured that the varied clinical practice observed internationally was 
represented equitably. Preset thresholds for the voting process also ensured that agreement 
was measurable and representative, lending credence and robustness to the process and 
reported outcomes
10
. The results, namely 34 agreed statements encompassing wide-ranging 
aspects of ICGCT management, including diagnostic work-up, staging, treatment and follow-
up, represent a contemporary opinion by international leaders in the field and are a key 
foundation for further advancing ICGCT management. Key aspects of these statements are 
highlighted further below. 
Areas of consensus. Despite varied approaches across continents in the management of these 
tumours, substantial areas of agreement were reached. Firstly, although it was agreed that a 
new term to describe ‘non-germinomatous’ ICGCTs was required (Statement 1), as many of 
these are mixed tumours and some include germinoma with other non-germinomatous 
components, there was no agreement on what that term might be. Participants were cognizant 
that suggestions such as ‘mixed malignant’ ICGCTs would miss pure malignant tumours, and 
that terms such as ‘secreting’ would miss embryonal carcinoma components. Pragmatically, 
it was suggested that it may be easier in the future to attempt to align classification systems 
internationally to identify a ‘common language’, rather than attempt to define a single term 
for these tumours. Participants agreed that ICGCTs are complex neoplasms (Statement 4) 
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requiring specialist and multi-disciplinary input and team-working through MDTs (Statement 
5). There was a strong acknowledgement that due to the excellent OS for germinoma, 
strategies should focus on reducing the late-effects of treatment (Statement 2), whereas for 
ICGCTs with non-germinomatous malignant components (i.e. NGGCTs), the aim should 
primarily be to improve OS (Statement 3).  
In diagnostic work-up, MRI is the investigation of choice for neuroimaging (Statement 6), 
rather than the less sensitive modality of CT scanning. While treatment is recommended in 
centres of excellence with access to MRI, the statement however acknowledges that in some 
resource-poor countries, MRI may be difficult to achieve. In addition, at diagnosis, all 
patients should have serum (Statement 9) and CSF (Statement 10) AFP and HCG markers 
measured, the only exception to the latter being if medically contra-indicated, and ideally at 
the same time (Statement 11). It was also agreed that CSF cytology should be performed 
where treatment protocol decisions are based on the results (Statement 7).  The importance of 
clearly documenting the site from which CSF was obtained was highlighted (Statement 12), 
particularly as most participants preferred lumbar CSF to ventricular CSF for cytological 
examination (Statement 8). Whilst lumbar CSF, usually taken 10-14 days post-operatively, is 
considered gold standard for staging malignant brain tumours by many neurooncologists, 
some argue that the evidence for this approach is not strong enough. A prospective 
institutional trial documented diagnostic superiority of CSF cytology obtained via lumbar tap 
over ventricular aspiration for identifying disseminated disease; however, only three of 52 
patients included in this study had germinoma
12
. The majority of cases described were 
medulloblastoma, located in the posterior fossa/4
th
 ventricular region
12
, where the distribution 
of metastases may be very different from more centrally located ICGCTs. For marker 
estimation, recent publications suggest that lumbar CSF is more sensitive for detecting HCG 
than either ventricular CSF
13
 or serum
14
. In contrast, as intra-ventricular lepto-meningeal 
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spread of malignant cells is more common than spread to the spine in germinoma, some 
groups believe that ventricular CSF is superior for detecting disease in this patient group, 
whereas lumbar CSF should be reserved for NGGCT cases. Others would argue that 
ventricular CSF may result in the over-staging of only regionally disseminated germinoma 
patients, committing them to craniospinal irradiation, when more focal RT fields, at least 
including the whole ventricles, may well be sufficient for cure. Careful documentation of site 
of CSF sampling (Statement 8) in future clinical trials may help to answer these outstanding 
questions.   
Participants agreed that the initial surgical management of obstructive hydrocephalus is CSF 
diversion (Statement 13) and that in such circumstances, CSF should be sent for AFP/HCG 
estimation first, at the time of surgery, but prior to tumour manipulation (Statement 14). 
Endoscopic third ventriculostomy (ETV), where feasible, is the favoured surgical CSF 
diversion procedure (Statement 15) and if not, an external ventricular drain (EVD), where 
feasible, is favoured over a permanent ventricular shunt (Statement 16). This statement 
reflects an experience shared by many experts in the field that chemotherapy, especially in 
the context of chemosensitive germinoma, results in rapid tumour shrinkage and re-opening 
of the CSF pathways within days. Hence a permanent shunt, with its inherent potential 
complications, can be avoided. 
From a surgical perspective, all patients with AFP and/or HCG levels below national protocol 
thresholds require surgical biopsy (Statement 17) and conversely, those with consistent 
radiological imaging and AFP and/or HCG elevation above national thresholds do not require 
surgical biopsy for ICGCT diagnosis (Statement 18), but instead treatment may be initiated, 
based on the diagnosis suggested by the markers. An area for future consensus will be to try 
and define common marker thresholds, as it is acknowledged that these vary across 
continents. It was agreed that the WHO classification of CNS tumours should be used as the 
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current international standard for pathological classification of ICGCTs (Statement 19), 
although it was hoped that in the future molecular markers may contribute to a revised 
classification. A minimum immunohistochemical panel for ICGCT diagnostic work-up was 
also defined (Statement 20). However, there was no agreement for a routine second 
pathological review, with participants stating that with current infrastructure this should only 
take place where diagnostic uncertainty existed or where mandated by clinical trials. 
Regarding treatment, complete surgical resection, where safely feasible, is recommended for 
intracranial teratomas and curative for the majority of those teratomas without malignant 
transformation (Statement 21). For intracranial germinoma, it was agreed that all patients 
should receive RT to maximise their chance of cure (Statement 22), except in infants and 
very young children due to the devastating neuropsychological sequelae encountered when 
irradiating the developing brain. Age thresholds for dismissing whole brain radiation as part 
of brain tumour treatment vary from <3 to <5 years, depending on institutions and countries. 
It was recognised that for patients with localised germinoma, at least whole ventricular RT 
should be used (Statement 23) and chemotherapy may be utilised to reduce the RT dose 
(Statement 24)
15
, questions also currently being studied in ongoing trials such as the 
European SIOP CNS GCT II trial and the North American ACNS 1123 trial. Patients with 
NGGCTs should receive a combination of chemotherapy and RT, to maximise their chance 
of cure (Statement 25), again except for very young children. For patients with metastatic 
NGGCTs craniospinal RT should be included in the treatment plan (Statement 26). For 
NGGCT, residual disease should be surgically resected, if feasible, prior to completion of 
therapy (Statement 27), as residuals are associated with a worse outcome
4
 and/or may 
represent the phenomenon of growing teratoma syndrome. The exact timing depends on 
treatment protocols. In Europe and America, this would most commonly occur post-
chemotherapy but prior to RT, whereas in Japan this would be at the completion of both 
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chemotherapy and RT. In contrast, the SIOP CNS germinoma trial did not find any evidence 
that residual germinoma at the end of treatment is associated with inferior outcomes
16
. 
For relapse, all patients should be fully re-staged and assessed, prior to considering 
management options (Statement 29), to allow delivery of the most appropriate treatment. It 
was agreed that relapsed germinoma patients are salvageable with variable, but not yet 
standardised, treatment regimens (Statement 30), but with no clear consensus as to whether 
standard or high-dose chemotherapy regimens offered the best outcomes. This uncertainty, at 
least in part, reflects the excellent outcomes from first line germinoma treatment and the 
rarity of relapse. This is in alignment with a European retrospective review of treatment 
regimens utilised for a small cohort of relapsed germinoma patients treated within SIOP CNS 
GCT 96 trial at initial diagnosis
17
. Good salvage rates were seen using various standard and 
high-dose chemotherapeutic regimes, with no clear indication to support one approach over 
another
17
. In the future, as a first step, it would be beneficial to agree appropriate and 
homogeneous data collection, to facilitate comparison of survival and late-effects outcomes, 
in order to develop recommendations or even guidelines on the optimal relapse strategy. It 
was agreed that for patients with relapsed NGGCTs, who are to be treated with curative 
intent, high-dose chemotherapy with haematopoietic stem cell rescue should be employed 
(Statement 31)
18
, although a minority of participants highlighted that the evidence base for 
this statement was weak. More published series of such relapsed cases are required to help 
inform such decisions. 
Banking of tumours and associated samples was strongly recommended (Statement 32), to 
support molecular studies of ICGCTs and facilitate recent progress
6,7
. We acknowledge that 
tumour banking per se may be ethically difficult to undertake in certain settings, especially as 
a biopsy is considered unnecessary for diagnostic purposes in the presence of raised 
AFP/HCG markers above national thresholds. However, the collection of associated samples 
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such as serum/plasma, CSF and constitutional DNA is of critical importance, as in the future 
these specimens may provide a relatively non-invasive method for identifying molecular 
changes that are representative of those in the tumours, thereby assisting diagnosis and risk 
stratification. For example, specific short non-protein-coding RNAs, termed microRNAs, are 
known to be dysregulated in all malignant GCTs
22
 and the same microRNAs have been 
shown to be elevated at diagnosis in serum
23,24
 and CSF
25
 from patients with extracranial and 
intracranial malignant GCTs, respectively. The importance of embedding quality of life 
(QoL) and late-effects assessments in clinical trials (Statements 33 and 34, respectively) was 
also highlighted. 
Areas of non-consensus. A number of statements did not reach consensus, even after 
revision. The current ongoing trials in North America (ACNS 1123) and Europe (SIOP CNS 
GCT II) consider synchronous lesions occurring in both the neurohypophyseal/suprasellar 
and pineal region with typical imaging characteristics, and with negative serum and CSF AFP 
markers, consistent with a diagnosis of bifocal germinoma, and trial enrolment is possible 
without surgical biopsy. This clinical scenario was included as one of the original 38 Delphi 
statements but was rejected. Based on participants’ comments, it was revised and the 
presence of diabetes insipidus was included; however, in the second round of voting, this was 
still clearly rejected, receiving only 49% support. Participants commented that a proportion of 
these cases can be NGGCT (e.g. EC with negative markers)
19,20
, or even a non-ICGCT 
diagnosis (e.g. primitive neuroectodermal tumour;
21
). Concern was expressed that without 
biopsy, the risk would be under-treating some of these patients using germinoma protocols, 
when more aggressive malignant components may be present. This is an area where expert 
opinion was clearly divided and it is hoped that future study results may help to resolve this 
area of controversy. 
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Another statement where a consensus was not reached was for metastatic germinoma 
documented on craniospinal imaging. One of the original statements listed that craniospinal 
irradiation alone is a sufficient treatment in this situation. This statement was rejected (48% 
agreement); although participants felt that historically this had been the standard of care, 
many thought that by accepting it, it would preclude further attempts to use chemotherapy in 
order to reduce the RT dose and thus long-term morbidity. The statement was therefore 
revised to reflect these views, adding that craniospinal irradiation alone is sufficient treatment 
to secure excellent overall survival, but the use of pre-radiation chemotherapy may allow for 
a reduction in RT dose. This revised statement was narrowly defeated (64% agreement); a 
minority of participants then commented that there was currently no evidence for this 
statement. 
Future challenges. The last decade has seen some international convergence of approaches 
in the management of ICGCTs
2
, and the Delphi process has managed to identify substantial 
areas of agreement that will facilitate future collaboration. However, a number of recognised 
challenges remain, some of which were not addressed in this initial Delphi process, as the 
primary aim in this initial consensus was to find and document the areas where agreement 
could be reached. These challenges will need further discussion, and include the following: 
the timing and extent of surgery, particularly at the time of diagnosis; the need to attempt to 
align the disparate classification systems used internationally for germinoma and NGGCT; 
potentially coining a new term for NGGCT, evaluation of reduced RT doses to cure localised 
germinoma without increasing relapse rates; the need for further evidence for the 
management of relapsed disease; how new molecular markers may be incorporated into 
future clinical trials; and the specific identification of strategies to reduce long-term side 
effects of treatment. 
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Application to other areas of oncology. We believe that the Delphi process could be applied 
to draw together experts in other areas of oncology, particularly areas of paediatric neuro-
oncology, which are relatively small subspecialties, in order to similarly identify areas of 
consensus. In doing so, it will be important to engage recognised experts from multiple 
disciplines and continents, to ensure equitable representation of observed variations in 
clinical practice. In turn, this will ensure the most robust statements are agreed, which will 
maximise the chance of positively impacting upon subsequent patient outcomes. 
Conclusion. The Delphi consensus statements reported here are a contemporary 
representative opinion by international leaders in the field and a key foundation for further 
advancement in ICGCT management. In addition, the process has identified areas of 
contrasting practices and understanding which should be the focus for future collaborative 
studies. Such efforts will likely facilitate international cooperation and translate into 
improved patient outcomes. 
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Legends to Figures 
Figure 1. Schematic of the Delphi consensus process for the management of intracranial 
germ cell tumours.  
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